MAIA Biotechnology, Inc., 2026-01-05
An SEC Form D private-offering notice from Chicago, IL, a $2,000,000 filer-stated offering target in Biotech. Filed 2026-01-05. The source filing is one click away. For companies that filed this week, open the live feed.
What this filing says
Clinical stage immuno-oncology company developing ateganosine (THIO), a telomere targeting cancer therapy, publicly traded on NYSE American.
This is a public SEC Form D private-offering notice, the filer's own statement to the SEC. Amounts are offering targets, not confirmed closes. Takeoff Radar pulls Form D nightly from EDGAR and links every filing to its source.
Other Form D filings from the same week
each with its own page and its own EDGAR source- Bitcoin Culture Hub Inc., 2026-01-13, $35K, Hinsdale, IL
- Harvard Apparatus Regenerative Technology, Inc., 2026-01-06, $2M, Holliston, MA
- Architect Financial Technologies Inc., 2026-01-13, $40.5M, Chicago, IL
- ClinTrial Research, Inc., 2026-01-05, $5M, Holly Springs, NC
- AssetBlue Impact Technologies, PBC, 2026-01-08, $4.9M, Chicago, IL
- ADAPTIN BIO, INC., 2026-01-05, $4M, Charlotte, NC
The Monday digest, free
A summary of who raised money last week: the ones worth a call first, then every company that filed, by state and sector. One email, Monday mornings. No spam, unsubscribe anytime.
By subscribing you agree to our Terms and Privacy Policy.